Scholarlink

Purpose <p>To investigate the association between primary tumor metabolic parameters on <sup>18</sup>F-FDG PET/CT and lymph node metastasis (LNM) in treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and to evaluate their utility in discriminating the cases with radiographically occult LNM (OLNM).</p> Methods <p>We retrospectively analyzed 157 patients with pathologically confirmed ALK-positive NSCLC who underwent <sup>18</sup>F-FDG PET/CT before the treatment between October 2021 and December 2024. Primary tumor metabolic parameters, including SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured. Logistic regression analyses were performed to identify LNM predictors. Receiver operating characteristic curve analysis evaluated predictive performance, with area under the curve (AUC) was calculated. The relation between OLNM status and metabolic parameters of primary tumor was analyzed using Kruskal-Wallis test.</p> Results <p>Among 157 patients (62 males and 95 females; mean age 56 ± 11 years), 71 patients (45.2%) had pathologically confirmed LNM. Patients with LNM exhibited evidently larger primary tumor size and higher SUVmax, SUVpeak, MTV, and TLG than those without LNM (all <i>P</i> &lt; 0.001). Univariate analysis showed primary tumor size, SUVmax, SUVpeak, MTV, and TLG were remarkedly associated with LNM. Multivariate analysis identified primary tumor size (OR: 1.043, 95%CI: 1.004–1.084; <i>P</i> = 0.032) and SUVmax (OR: 1.322, 95%CI: 1.159–1.532; <i>P</i> &lt; 0.001) as independent predictors. The AUCs for tumor size, SUVmax, and combined factors were 0.76, 0.77, and 0.81, respectively. In addition, false-negative (OLNM-positive) cases showed markedly larger tumor size (<i>P</i> = 0.003) and higher TLG (<i>P</i> = 0.011) than true-negative cases.</p> Conclusion <p>Metabolic parameters of <sup>18</sup>F-FDG PET/CT before treatment, particularly when combined with primary tumor size, may help stratify LNM risk in treatment-naïve ALK-positive NSCLC patients. These parameters may help identify OLNM, potentially guiding personalized lymph node dissection strategies and optimizing treatment plans.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Predictive value of primary tumor 18F-FDG PET/CT metabolic parameters for lymph node metastasis in treatment-naïve ALK-positive NSCLC

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月29日

查看全文
  • Tingting Qiao,
  • Jie Gu,
  • Yangchun Chen,
  • Juan Zhao

摘要

Purpose

To investigate the association between primary tumor metabolic parameters on 18F-FDG PET/CT and lymph node metastasis (LNM) in treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC), and to evaluate their utility in discriminating the cases with radiographically occult LNM (OLNM).

Methods

We retrospectively analyzed 157 patients with pathologically confirmed ALK-positive NSCLC who underwent 18F-FDG PET/CT before the treatment between October 2021 and December 2024. Primary tumor metabolic parameters, including SUVmax, SUVpeak, metabolic tumor volume (MTV), and total lesion glycolysis (TLG), were measured. Logistic regression analyses were performed to identify LNM predictors. Receiver operating characteristic curve analysis evaluated predictive performance, with area under the curve (AUC) was calculated. The relation between OLNM status and metabolic parameters of primary tumor was analyzed using Kruskal-Wallis test.

Results

Among 157 patients (62 males and 95 females; mean age 56 ± 11 years), 71 patients (45.2%) had pathologically confirmed LNM. Patients with LNM exhibited evidently larger primary tumor size and higher SUVmax, SUVpeak, MTV, and TLG than those without LNM (all P < 0.001). Univariate analysis showed primary tumor size, SUVmax, SUVpeak, MTV, and TLG were remarkedly associated with LNM. Multivariate analysis identified primary tumor size (OR: 1.043, 95%CI: 1.004–1.084; P = 0.032) and SUVmax (OR: 1.322, 95%CI: 1.159–1.532; P < 0.001) as independent predictors. The AUCs for tumor size, SUVmax, and combined factors were 0.76, 0.77, and 0.81, respectively. In addition, false-negative (OLNM-positive) cases showed markedly larger tumor size (P = 0.003) and higher TLG (P = 0.011) than true-negative cases.

Conclusion

Metabolic parameters of 18F-FDG PET/CT before treatment, particularly when combined with primary tumor size, may help stratify LNM risk in treatment-naïve ALK-positive NSCLC patients. These parameters may help identify OLNM, potentially guiding personalized lymph node dissection strategies and optimizing treatment plans.